JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.